Dr. Paoletti, was the first appointed president of GSK Oncology. As the leader of the global business unit of 2,000 professionals, he held accountability for the overall oncology business within GSK and oversaw all activities from early drug discovery through clinical development, launch and life cycle management. During his tenure at GSK, seven new medicines to treat cancer were approved globally, generating annual sales of about US$2 billion. Prior to joining GSK, Dr. Paoletti was Vice President of Oncology Clinical Research at Lilly, where he developed ALIMTA. He is a former PsiOxus Board Chairman, currently CEO of GammaDelta Therapeutics, and a non-executive director for Genmab and FORMA Therapeutics. Dr. Paoletti has a degree in Medicine from the University of Pisa (Italy) where he was professor in Pulmonary Diseases and authored more than 300 publications.